000280782 001__ 280782
000280782 005__ 20250907001856.0
000280782 0247_ $$2doi$$a10.1002/alz.70588
000280782 0247_ $$2pmid$$apmid:40851076
000280782 0247_ $$2pmc$$apmc:PMC12375433
000280782 0247_ $$2ISSN$$a1552-5260
000280782 0247_ $$2ISSN$$a1552-5279
000280782 0247_ $$2altmetric$$aaltmetric:180758778
000280782 037__ $$aDZNE-2025-00966
000280782 041__ $$aEnglish
000280782 082__ $$a610
000280782 1001_ $$0P:(DE-2719)9001475$$aKobeleva, Xenia$$b0
000280782 245__ $$aAlterations in MRI-visible perivascular spaces precede dementia diagnosis by 18 years in autosomal dominant Alzheimer's disease.
000280782 260__ $$aHoboken, NJ$$bWiley$$c2025
000280782 3367_ $$2DRIVER$$aarticle
000280782 3367_ $$2DataCite$$aOutput Types/Journal article
000280782 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1756976625_4385
000280782 3367_ $$2BibTeX$$aARTICLE
000280782 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000280782 3367_ $$00$$2EndNote$$aJournal Article
000280782 520__ $$aPerivascular space (PVS) alterations are traditionally linked to cardiovascular risk factors and aging, but may also play a direct role in Alzheimer's disease (AD). To reduce confounding from age-related comorbidities, we examined PVSs in autosomal dominant AD (ADAD).In this cross-sectional study of 96 non-demented individuals (62 mutation carriers), we quantified PVS count fraction and mean diameter in white matter and basal ganglia using automated magnetic resonance imaging analysis. Linear mixed models assessed group differences along the disease course, adjusting for cardiovascular risk factors.Compared to non-carriers, mutation carriers showed lower PVS count fraction in white matter and basal ganglia, and larger PVS diameter in basal ganglia and the temporal lobe. Changes were evident up to 18 years before expected dementia onset and followed trajectories similar to amyloid beta 42 and tau biomarkers.ADAD is associated with early PVS alterations, suggesting perivascular changes may be integral to primary AD pathology.Autosomal dominant Alzheimer's disease (ADAD) mutation carriers have reduced magnetic resonance imaging-visible perivascular space (PVS) count fraction in the white matter and basal ganglia. ADAD mutation carriers show enlarged PVS in the basal ganglia and temporal white matter. PVS alterations start 18 years before the estimated time of dementia diagnosis. The spatial localization of PVS changes overlaps with regions of amyloid beta (Aβ) accumulation. The temporal evolution of PVS alterations aligns with Aβ and tau changes in the cerebrospinal fluid.
000280782 536__ $$0G:(DE-HGF)POF4-353$$a353 - Clinical and Health Care Research (POF4-353)$$cPOF4-353$$fPOF IV$$x0
000280782 588__ $$aDataset connected to CrossRef, PubMed, , Journals: pub.dzne.de
000280782 650_7 $$2Other$$aAlzheimer's disease
000280782 650_7 $$2Other$$aautosomal dominant Alzheimer's disease
000280782 650_7 $$2Other$$acerebral small vessel disease
000280782 650_7 $$2Other$$adominantly inherited Alzheimer's disease
000280782 650_7 $$2Other$$amagnetic resonance imaging
000280782 650_7 $$2Other$$aperivascular spaces
000280782 650_7 $$2NLM Chemicals$$aAmyloid beta-Peptides
000280782 650_7 $$2NLM Chemicals$$atau Proteins
000280782 650_2 $$2MeSH$$aHumans
000280782 650_2 $$2MeSH$$aMale
000280782 650_2 $$2MeSH$$aFemale
000280782 650_2 $$2MeSH$$aMagnetic Resonance Imaging
000280782 650_2 $$2MeSH$$aAlzheimer Disease: genetics
000280782 650_2 $$2MeSH$$aAlzheimer Disease: pathology
000280782 650_2 $$2MeSH$$aAlzheimer Disease: diagnostic imaging
000280782 650_2 $$2MeSH$$aCross-Sectional Studies
000280782 650_2 $$2MeSH$$aMiddle Aged
000280782 650_2 $$2MeSH$$aWhite Matter: diagnostic imaging
000280782 650_2 $$2MeSH$$aWhite Matter: pathology
000280782 650_2 $$2MeSH$$aGlymphatic System: diagnostic imaging
000280782 650_2 $$2MeSH$$aGlymphatic System: pathology
000280782 650_2 $$2MeSH$$aBasal Ganglia: pathology
000280782 650_2 $$2MeSH$$aBasal Ganglia: diagnostic imaging
000280782 650_2 $$2MeSH$$aMutation: genetics
000280782 650_2 $$2MeSH$$aAged
000280782 650_2 $$2MeSH$$aAmyloid beta-Peptides: cerebrospinal fluid
000280782 650_2 $$2MeSH$$atau Proteins: cerebrospinal fluid
000280782 650_2 $$2MeSH$$aDisease Progression
000280782 7001_ $$aRowe, Bryan$$b1
000280782 7001_ $$aChoupan, Jeiran$$b2
000280782 7001_ $$aRingman, John M$$b3
000280782 7001_ $$00000-0001-5598-1369$$aBarisano, Giuseppe$$b4
000280782 7001_ $$0P:(DE-2719)9002420$$aLeone, Riccardo$$b5$$eFirst author
000280782 773__ $$0PERI:(DE-600)2201940-6$$a10.1002/alz.70588$$gVol. 21, no. 8, p. e70588$$n8$$pe70588$$tAlzheimer's and dementia$$v21$$x1552-5260$$y2025
000280782 8564_ $$uhttps://pub.dzne.de/record/280782/files/DZNE-2025-00966%20SUP1.docx
000280782 8564_ $$uhttps://pub.dzne.de/record/280782/files/DZNE-2025-00966%20SUP2.pdf
000280782 8564_ $$uhttps://pub.dzne.de/record/280782/files/DZNE-2025-00966.pdf$$yOpenAccess
000280782 8564_ $$uhttps://pub.dzne.de/record/280782/files/DZNE-2025-00966%20SUP2.pdf?subformat=pdfa$$xpdfa
000280782 8564_ $$uhttps://pub.dzne.de/record/280782/files/DZNE-2025-00966.pdf?subformat=pdfa$$xpdfa$$yOpenAccess
000280782 909CO $$ooai:pub.dzne.de:280782$$pdnbdelivery$$pdriver$$pVDB$$popen_access$$popenaire
000280782 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)9001475$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b0$$kDZNE
000280782 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)9002420$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b5$$kDZNE
000280782 9131_ $$0G:(DE-HGF)POF4-353$$1G:(DE-HGF)POF4-350$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lNeurodegenerative Diseases$$vClinical and Health Care Research$$x0
000280782 9141_ $$y2025
000280782 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2025-01-06
000280782 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2025-01-06
000280782 915__ $$0LIC:(DE-HGF)CCBYNCND4$$2HGFVOC$$aCreative Commons Attribution-NonCommercial-NoDerivs CC BY-NC-ND 4.0
000280782 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bALZHEIMERS DEMENT : 2022$$d2025-01-06
000280782 915__ $$0StatID:(DE-HGF)3001$$2StatID$$aDEAL Wiley$$d2025-01-06$$wger
000280782 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2025-01-06
000280782 915__ $$0StatID:(DE-HGF)9910$$2StatID$$aIF >= 10$$bALZHEIMERS DEMENT : 2022$$d2025-01-06
000280782 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2025-01-06
000280782 915__ $$0StatID:(DE-HGF)0510$$2StatID$$aOpenAccess
000280782 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2025-01-06
000280782 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2025-01-06
000280782 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2025-01-06
000280782 9201_ $$0I:(DE-2719)1011103$$kAG Spottke$$lClinical Research Platform (CRP)$$x0
000280782 9201_ $$0I:(DE-2719)1011401$$kClinical Research Platform (CRP)$$lClinical Research Platform (CRP)$$x1
000280782 9201_ $$0I:(DE-2719)1011001$$kClinical Research (Bonn)$$lClinical Research Coordination$$x2
000280782 980__ $$ajournal
000280782 980__ $$aVDB
000280782 980__ $$aUNRESTRICTED
000280782 980__ $$aI:(DE-2719)1011103
000280782 980__ $$aI:(DE-2719)1011401
000280782 980__ $$aI:(DE-2719)1011001
000280782 9801_ $$aFullTexts